Amarin vs. the Generics: Who Will Win?

Amarin can lose its patent fight over Vascepa and still win the prescription war.

Why did Wall Street whack Amarin? The stock market is very familiar with the "patent cliff" and how pharmaceutical stocks in particular can get killed when drugs go off-patent. So, for instance, when Pfizer lost its patent protection for Lipitor, billions of dollars in revenue evaporated.